ESBATech AG, a leading developer of antibody fragment therapeutics, today announced the initiation of a Phase IIa study in patients with acute anterior uveitis. This study is designed to evaluate the safety, to
Dr. Urech commented, "ESBATech's proprietary, repeatable screening platform was employed and generated multiple promising antibody fragment product candidates against several targets for topical ophthalmic use. Antibody fragments have a number of advantages over whole antib...
ESBATech's successful screening and characterization of all 1.5 million naturally occurring antibody fragment frameworks resulted in highly-stable, single-chain antibody fragments. These drug-like fragments are ideal for pioneering therapeutic interventions that require high ...